BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 33235387)

  • 21. HEPATOCELLULAR CARCINOMA: CURRENT AND PROSPECTIVE IMMUNOTHERAPEUTIC STRATEGIES.
    Kikodze N; Mazmishvili K; Iobadze M; Rekhviashvili Kh; Nanava N; Pantsulaia I; Mizandari M; Janikashvili N; Chikovani T
    Georgian Med News; 2015 Sep; (246):78-84. PubMed ID: 26355320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
    Dai X; Guo Y; Hu Y; Bao X; Zhu X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Fang W
    Theranostics; 2021; 11(7):3489-3501. PubMed ID: 33537099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Revamping the innate or innate-like immune cell-based therapy for hepatocellular carcinoma: new mechanistic insights and advanced opportunities.
    Shah DD; Dave BP; Patel PA; Chorawala MR; Patel VN; Shah PA; Patel MP
    Med Oncol; 2023 Jan; 40(2):84. PubMed ID: 36680649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospects and Challenges for T Cell-Based Therapies of HCC.
    Woller N; Engelskircher SA; Wirth T; Wedemeyer H
    Cells; 2021 Jun; 10(7):. PubMed ID: 34209393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The yin and yang of evasion and immune activation in HCC.
    Makarova-Rusher OV; Medina-Echeverz J; Duffy AG; Greten TF
    J Hepatol; 2015 Jun; 62(6):1420-9. PubMed ID: 25733155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint inhibitors for hepatocellular carcinoma.
    El Dika I; Khalil DN; Abou-Alfa GK
    Cancer; 2019 Oct; 125(19):3312-3319. PubMed ID: 31290997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches.
    Kalathil SG; Thanavala Y
    Cells; 2021 May; 10(6):. PubMed ID: 34071188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
    Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
    Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autophagy in the "inflammation-carcinogenesis" pathway of liver and HCC immunotherapy.
    Yu S; Wang Y; Jing L; Claret FX; Li Q; Tian T; Liang X; Ruan Z; Jiang L; Yao Y; Nan K; Lv Y; Guo H
    Cancer Lett; 2017 Dec; 411():82-89. PubMed ID: 28987386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for hepatocellular carcinoma.
    Zongyi Y; Xiaowu L
    Cancer Lett; 2020 Feb; 470():8-17. PubMed ID: 31811905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunobiology of hepatocellular carcinoma.
    Flecken T; Spangenberg HC; Thimme R
    Langenbecks Arch Surg; 2012 Jun; 397(5):673-80. PubMed ID: 21479622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy in hepatocellular cancer.
    Fountzilas C; Evans R; Alaklabi S; Iyer R
    Adv Cancer Res; 2021; 149():295-320. PubMed ID: 33579426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities.
    Lu C; Rong D; Zhang B; Zheng W; Wang X; Chen Z; Tang W
    Mol Cancer; 2019 Aug; 18(1):130. PubMed ID: 31464625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy for hepatocellular carcinoma.
    Li S; Yang F; Ren X
    Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects.
    Roudi R; D'Angelo A; Sirico M; Sobhani N
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108322. PubMed ID: 34735916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
    Oura K; Morishita A; Tani J; Masaki T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
    Choi C; Yoo GS; Cho WK; Park HC
    World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
    Pfister D; Núñez NG; Pinyol R; Govaere O; Pinter M; Szydlowska M; Gupta R; Qiu M; Deczkowska A; Weiner A; Müller F; Sinha A; Friebel E; Engleitner T; Lenggenhager D; Moncsek A; Heide D; Stirm K; Kosla J; Kotsiliti E; Leone V; Dudek M; Yousuf S; Inverso D; Singh I; Teijeiro A; Castet F; Montironi C; Haber PK; Tiniakos D; Bedossa P; Cockell S; Younes R; Vacca M; Marra F; Schattenberg JM; Allison M; Bugianesi E; Ratziu V; Pressiani T; D'Alessio A; Personeni N; Rimassa L; Daly AK; Scheiner B; Pomej K; Kirstein MM; Vogel A; Peck-Radosavljevic M; Hucke F; Finkelmeier F; Waidmann O; Trojan J; Schulze K; Wege H; Koch S; Weinmann A; Bueter M; Rössler F; Siebenhüner A; De Dosso S; Mallm JP; Umansky V; Jugold M; Luedde T; Schietinger A; Schirmacher P; Emu B; Augustin HG; Billeter A; Müller-Stich B; Kikuchi H; Duda DG; Kütting F; Waldschmidt DT; Ebert MP; Rahbari N; Mei HE; Schulz AR; Ringelhan M; Malek N; Spahn S; Bitzer M; Ruiz de Galarreta M; Lujambio A; Dufour JF; Marron TU; Kaseb A; Kudo M; Huang YH; Djouder N; Wolter K; Zender L; Marche PN; Decaens T; Pinato DJ; Rad R; Mertens JC; Weber A; Unger K; Meissner F; Roth S; Jilkova ZM; Claassen M; Anstee QM; Amit I; Knolle P; Becher B; Llovet JM; Heikenwalder M
    Nature; 2021 Apr; 592(7854):450-456. PubMed ID: 33762733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.